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Abstract
Background: Malignant struma ovarii is a rare malignant germ cell tumor of the ovary. Due to the rarity of this disease, 
treatment has not been uniform throughout the published literature.
Cases: We present three cases of malignant struma ovarii. Following primary surgery, all were subsequently treated with 
thyroidectomy and ¹³¹I ablation therapy, two patients as ﬁ  rst line management, one following the occurrence of metastatic 
disease.
Conclusion: Histological diagnosis of malignant struma ovarii is similar to that of well differentiated thyroid carcinoma 
(WDTC). In line with the latest advice on treatment of WDTC, we believe that the best option for patients with malignant 
struma ovarii is surgical removal of the ovarian lesion followed by total thyroidectomy which allows the exclusion of primary 
thyroid carcinoma, and in addition, allows radioiodine (¹³¹I) ablation therapy for (micro) metastasis. After thyroidectomy, 
thyroglobulin can be used as a tumor marker for follow-up. Moreover, nuclear medicine imaging using radioiodine (¹²³I) 
can be performed to demonstrate metastatic carcinoma. A multidisciplinary approach is essential.
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Introduction
The diagnosis of malignant struma ovarii is based on classical criteria for papillary or follicular thyroid 
carcinoma including overlapping ground glass nuclei in the former and vascular space invasion and 
capsular penetration in the latter. Malignancy is more likely in tumors larger than 16 cm or when 
metastatic seeding of the peritoneum is present, so called “strumosis” (Young, 1993; Ayhan et al. 1993). 
The peak incidence lies between 40 and 60 years of age (Ross DS. 2005 UpToDate
® ‘Struma ovarii’ 
http/www.utdol.com/utd/content/). Patients often present with pelvic pain or irregular menstrual bleed-
ings (Devaney et al. 1993; DeSimone et al. 2003; Makani et al. 2004), whereas a minority (10%) has 
symptoms consistent with hyperthyroidism. Transvaginal examination may reveal a cyst, often with 
septae or solid areas. This may mimic an endometrial- or dermoid cyst.
The rarity of tumors such as malignant struma ovarii precludes any uniform management sugges-
tions, other than attempting complete cytoreductive surgery. Surgery is needed for diagnosis, surgical 
staging, and deﬁ  nitive treatment. Therapy depends on age: for women of childbearing age it is recom-
mended to preserve uterus and contra lateral ovary if they appear to be normal. Total abdominal hys-
terectomy and bilateral salpingo-oophorectomy should be performed in women who have completed 
childbearing. Adjuvant therapies should be geared toward the transformed component.
Metastases from malignant struma ovarii are rare (5%) (Willemse et al. 1987; Rose et al. 1998; 
DeSimone et al. 2003). Metastases from a primary thyroid carcinoma simulating struma ovarii are even 
rarer (Makani et al. 2004).148
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This article will review three patients with 
malignant struma ovarii, its therapy and follow-up, 
who were treated in our clinic. In addition recom-
mendations regarding potential treatment options 
are given.
Case Reports
Patient A
A 33-year-old, para 1 complained of progressive 
lower abdominal pain and stress incontinence. 
Physical examination revealed an immobile, ﬁ  rm 
tumor extending in the right lower quadrant of the 
abdomen to 2 cm below the umbilicus. Trans-
vaginal ultrasound revealed a 10 × 15 cm cyst with 
solid parts. A laparotomy was performed; the right 
adnex, adherent to the right pelvic wall, was 
removed. Frozen section of this partly cystic, partly 
solid mass gave no deﬁ  nite diagnosis, therefore the 
uterus and left adnex were removed (TAH + BSO). 
Macroscopically all tumor was removed. Histology 
showed the follicular variant of a papillary thyroid 
carcinoma arising in a struma ovarii.
After three years follow-up the patient again 
complained of abdominal pain and bladder prob-
lems. There was no weight loss and no symptoms 
of anxiety. Both ultrasound and MRI studies 
showed multiple liver metastases and suspicious 
lymph nodes along the right iliac artery. Fine 
needle biopsy conﬁ  rmed the presence of metasta-
ses from a papillary thyroid carcinoma. In order to 
treat these metastases with radioiodine a total 
thyroidectomy was performed. Histology of the 
thyroid gland was normal. Postthyroidectomy 
thyroglobulin levels were 607 µg/l (normal value 
1–20 µg/l). Subsequently she received a total of 
three doses of ¹³¹I in doses of 5550 MBq, 1850 MBq 
and 5550 MBq respectively with intervals of 
6 months. Each treatment was followed 24 hours 
later by a total body scintigram: liver uptake dimin-
ished over time from 40% to 17% (see Fig. 1). No 
new sites of tumor formation occurred over time. 
With this treatment she reached stable disease, 
which up to now lasts for four years. Serum thy-
roglobulin levels have stabilized at levels amount-
ing to112 ug/l since the last ¹³¹I therapy.
Patient B
A 52-year-old, para 3, postmenopausal woman was 
found to have an ovarian cyst at routine check-up. 
Figure 1. Total body scintigraphy eight days after 5550 MBq. 
131I treatment. Intense and multifocal laesions in the liver (*) and 
abdomen (**).149
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There was unexplained weight loss of 11 kilograms 
during the preceding six months. Thyroid stimulat-
ing hormone (TSH) serum levels were normal. 
Ultrasound showed a 10 × 8 cm cyst with partitions 
and solid areas in the left ovary.
Laparotomy revealed a large grey, smooth cyst 
about 15 cm in diameter originating from the left 
ovary. A small amount of ascites was present. 
Frozen section of the left ovary was inconclusive, 
so bilateral salpingo-oophorectomy was performed. 
Histology revealed follicular carcinoma in a struma 
ovarii (see Fig. 2). Subsequently a total thyroidec-
tomy was performed, showing a papillary thyroid 
micro carcinoma of 3 mm (see Fig. 3). ¹²³I-scintig-
raphy showed only little uptake in the thyroid 
gland. Thyroglobulin serum levels were undetect-
able. Ablative therapy was given with a dose of 
5550 MBq ¹³¹I . Two years after this treatment there 
is no evidence for recurrence.
Patient C
A 32-year-old, para 0 complained about prolonged 
diarrhea without weight loss. She had lower 
abdominal pain. She had regular withdrawal bleed-
ings with oral contraceptives. The patient wished 
to conceive in the future. Ultrasound revealed 
ascites and a cystic left ovary 8 × 4 cm. At lapa-
rotomy the cyst was found to be fused with the 
serosa of the small intestines. In order to allow 
complete excision a colostomy was performed 
along with a unilateral oophorectomy. Histology 
revealed a papillary carcinoma in struma ovarii. 
After total thyroidectomy, ¹³¹I ablation therapy with 
5550 MBq and ¹²³I scintigraphy followed. The 
scintigram showed minimal pathological rest-
activity behind the bladder (see Fig. 4). Because 
the patient had anti-thyroglobulin antibodies, 
serum thyroglobulin could not be used as a tumor 
marker. Six months after the ﬁ  rst operation the 
colostomy was discontinued. Inspection of the 
abdomen did not reveal any macroscopic tumor. 
Recently a total body scintigram was performed, 
which did not show evidence for remaining dis-
ease. The pathological rest activity behind the 
bladder might have disappeared due to the lasting 
effect of ¹³¹I ablation therapy.
Discussion
We reviewed three patients, two with papillary 
thyroid carcinoma, and one with follicular thyroid 
carcinoma in struma ovarii. Two of them presented 
with pain, two experienced symptoms (weight loss 
and diarrhea) which might have been caused by 
hyperthyroidism although TSH levels at the time 
were normal. All had enlarged cystic ovaries with 
an average diameter of 11 cm. One of our patients 
had a papillary thyroid micro carcinoma in the 
thyroid gland. In autopsy series such small papillary 
Figure 2. Follicular carcinoma in a struma ovarii.150
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Figure 3. Papillary thyroid carcinoma in thyroid gland.
Figure 4. Total body scintigraphy eight days after 5550 MBq. 
131I treatment. Two small spots in the region of the former thyroid are visible, 
probably remnant (*). In the pelvic region, there is pathological uptake visible just left of the bladder (**). This could be residual tumor activity.151
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carcinomas are found in about 25% (Yamamoto 
et al. 1990). Since histology in the thyroid and 
ovary differed, the struma ovarii was considered a 
primary tumor and not a metastasis.
Ultrasound can not speciﬁ  cally identify struma 
ovarii, however one must consider this diagnosis 
especially in solid looking teratomas. Pre-operative 
diagnosis of struma ovarii is only possible in 
patients with hyperthyroidism by measurement of 
serum TSH in combination with ¹²³I scintigraphy 
(Masuda et al. 2001). If one suspects struma ova-
rii, serum levels of free T4, thyroglobulin and TSH 
should be measured. In none of our patients this 
was done. Diagnoses were made on histology.
There is no universal therapy for malignant 
struma ovarii throughout the published literature. 
Surgery varies from laparoscopic unilateral oopho-
rectomy to TAH + BSO with omentectomy. Malig-
nant struma ovarii shows the same morphological 
features on histology as well differentiated (fol-
licular and papillary) thyroid carcinoma (WDTC). 
Like most authors we adhere to the recommenda-
tions given by Devaney and co-workers to use the 
same histological criteria to diagnose malignant 
struma ovarii as are used for tumors in the thyroid 
gland (Devaney et al. 1993; DeSimone et al. 2003; 
Makani et al. 2004). Likewise we share the opinion 
that therapy and follow up of malignant struma 
ovarii should be based on criteria for the treatment 
and follow up of WDTC. A recent consensus 
report on WDTC by Pacini and co-workers sug-
gests that radioiodine can reduce recurrences and 
possibly mortality when there is uncertainty about 
the completeness of thyroid surgery (Pacini et al. 
2005). According to this report radioiodine is 
deﬁ  nitely indicated in patients with distant metas-
tases, incomplete tumor resection, tumors 1 cm, 
suboptimal surgery (no lymph node resection), 
young age (16 years), and/or unfavorable histol-
ogy. Especially high-risk patients with T3, T4 or 
T × N1 or T × N × M1 tumors demonstrated sig-
niﬁ  cantly reduced recurrence and mortality rates 
at 20 years after ¹³¹I treatment as compared to 
patients who have not undergone ablative radioio-
dine treatment (Tubiana et al. 1985; Tsang et al. 
1998; Pacini et al. 2005). Applying these criteria 
to malignant struma ovarii would result in thyroid-
ectomy followed by postoperative ¹³¹I ablation 
therapy for most patients, since tumor size would 
exceed 1 cm in most, and lymph node resection is 
seldom performed. Total thyroidectomy following 
surgical removal of the ovarian lesion allows the 
exclusion of primary thyroid carcinoma with 
metastasis to the ovary and in addition, allows 
radioiodine (¹³¹I) therapy for treatment of (micro) 
metastasis. After thyroidectomy, thyroglobulin can 
be used as a tumor marker for follow-up. Moreover, 
nuclear medicine imaging using radioiodine (¹²³I) 
can be performed to demonstrate metastatic thyroid 
carcinoma. Unfortunately at the time patient A was 
diagnosed and treated we did not routinely perform 
thyroidectomy followed by nuclear medicine imag-
ing using radioiodine (¹²³I) as we did in patients B 
and C. This approach might have led to prevention 
or earlier detection of metastases. This patient 
shows that after recurrence ¹³¹I therapy has a ben-
eﬁ  cial effect on extensive metastatic disease how-
ever she is not disease free. Beneﬁ  cial effects of 
¹³¹I therapy have also been demonstrated by 
DeSimone and co-workers who reviewed the lit-
erature on malignant struma ovarii in a total series 
of 24 patients (DeSimone et al. 2003). This review 
reports a recurrence rate after initial complete 
response of 35%. All recurrences occurred in 
patients without primary adjuvant therapy. This 
supports us in the believe that ¹³¹I therapy should 
be ﬁ  rst line treatment. The above described advan-
tages outweigh the disadvantage of performing a 
thyroidectomy with its low morbidity (recurrent 
laryngeal nerve damage (1%), hypocalcemia 
(2%) and thyroid replacement therapy). The prac-
titioner should be aware that due to competition 
between iodine and radioiodine, no iodine (as 
disinfectant or contrast medium) should be used 
6 weeks prior to ¹³¹I ablation therapy or ¹²³I scin-
tigraphy.
Side-effects of ¹³¹I treatment are usually mild 
and most are reversible (Pacini et al. 2005). Tran-
sient amenorrhea and an early age of menopause 
have been observed (Ceccarelli et al. 2001). Stud-
ies of pregnancy outcome after radioiodine treat-
ment reveal no deleterious effects, although there 
is an increased risk of miscarriage when conception 
occurs within 6 months after the last treatment 
(Schlumberger et al. 1996). Fertile women should 
be advised about adequate contraception during 
treatment, and until 6 months thereafter.
Conclusion
Malignant struma ovarii is a rare gynecological 
endocrine- oncological disorder. Due to its rarity 
there is little information about the natural course 
of this disorder after surgical resection and the best 152
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postoperative treatment modalities. If the diagnosis 
of malignant struma ovarii can be made at the time 
of surgery, a complete surgical removal of the 
tumor should be done. In line with the treatment 
and follow-up of WDTC we believe that the best 
option for patients with malignant struma ovarii 
larger than one cm is total thyroidectomy followed 
by ¹³¹I ablation therapy. After ¹³¹I ablation any 
detectable serum thyroglobulin points to persistent 
or recurrent disease. After ablation, the highly 
sensitive post-ablation total body scan can dem-
onstrate completeness of surgical excision or 
indicate metastatic disease. A multidisciplinary 
approach is essential, whereby the gynecologist, 
surgeon, endocrinologist, pathologist and nuclear 
physician are working closely together.
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